Graft Polymer (UK) PLC (LSE:GPL) CEO Anthony Tennyson talked with Proactive's Stephen Gunnion about the company's promising preclinical program targeting mental health conditions such as post-traumatic stress disorder (PTSD).
Partnering with Eurofins Discovery, Graft Polymer is testing a potential treatment significant unmet need in PTSD treatment.
"Unfortunately, PTSD affects millions, with 13 million sufferers in the U.S. alone," Tennyson explained, adding that current treatments are limited, leaving a large addressable market. With Eurofins Discovery's expertise in research services, Graft Polymer is moving forward quickly and expects preclinical results by the end of November.